TABLE 4.

Hazard rations (HR), 95% confidence intervals (CI), and P-values from multivariable Cox regression models for 213 patients’ progression-free survival and overall survival from time of the first NANT enrollment

Variable	#PT	Progression-free survival			Overall survival
		HR(95%CI)	P-value	HR(95%CI)	P-value
Age at NANT tx start (years)		Excluded			0.033
<3	9			0.54 (0.19,1.5)
3–5	70			1.0
6–9	66			0.88 (0.58,1.3)
10–20	58			0.72 (0.47,1.1)
≥21	10			0.27(0.11,0.67)
MYCN			0.037	Excluded
Nonamplified	121	1.0
Amplified	39	1.6(1.03, 2.4)
Unknown	53d
Measurable tumor at enrollment on CT/MRI		Excluded			0.041
No	110			1.0
Yes	103			1.4 (1.01, 2.0)
Curie score at enrollment			<0.001a		0.001a
0	15	1.0		1.0
1–4	62	3.2 (1.6, 6.3)	0.048b	2.1(1.01,4.4)	0.037b
5–9	40	5.9 (2.7,13)		3.1 (1.4, 6.9)
10–19	47	5.0(2.4,11)		2.9 (1.3, 6.3)
20–25	16	5.1(2.1,12)		4.6(1.8,12)
Unknown but > 0c	29
Nonavidd	4
PBSC-supported trial			<0.001		0.003
No	86	1.0		1.0
Yes	127	0.34 (0.24,0.48)		0.57 (0.40,0.83)
Prior PD after dx of HR-NB			<0.001		<0.001
No	64	1.0		1.0
Yes	149	2.9 (2.0,4.3)		4.1 (2.6, 6.6)

PT, patients; dx, diagnosis; BM, bone marrow; tx, treatment; HR-NB, high-risk neuroblastoma; MIBG, meta-iodobenzylguanidine; PBSC, peripheral blood stem cell; PD, progressive disease; NANT, New Approaches to Neuroblastoma Therapy. For multivariable analyses, only variables significant in univariate analyses at P ≤ 0.05 were included, then a backward selection procedure was used to eliminate variables not significant at P ≤ 0.05.

^aTest of trend including all Curie scores.

^bTest of trend in patients with Curie score ≥1.

^cThese patients included in model as missing category.

^dThese patients excluded from analyses.